PARADIGM BIOPHARMACEUTICALS LIMITED (PAR)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PAR

PAR - PARADIGM BIOPHARMACEUTICALS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0
Index:

Paradigm Biopharmaceuticals is an Australian biotech company focused on the repurposing of the drug Pentosan Polysulphate Sodium for treatment of conditions sustained by inflammation. It has been listed since 2015.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.335

01 Oct
2025

0.000

OPEN

$0.34

0.000

HIGH

$0.35

2,030,280

LOW

$0.32

TARGET
$0.65 94.0% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
PAR: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx - 6.0 - 10.9 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-6.0
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.1 M
Book Value Per Share xxxxxxxxxxxxxxx5.4
Net Operating Cash Flow xxxxxxxxxxxxxxx-16.0 M
Net Profit Margin xxxxxxxxxxxxxxx-36,014.48 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-83.44 %
Return on Invested Capital xxxxxxxxxxxxxxx-83.23 %
Return on Assets xxxxxxxxxxxxxxx-72.25 %
Return on Equity xxxxxxxxxxxxxxx-83.44 %
Return on Total Capital xxxxxxxxxxxxxxx-101.19 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-16.0 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx17 M
Price To Book Value xxxxxxxxxxxxxxx5.61

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxxxxxxxx0.00 %
Cost of Goods Sold xxxxxxxxxxxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx23 M
Research & Development xxxxxxxxxxxxxxx18 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

01/10/2025

1

Speculative Buy

$0.65

94.03%

Paradigm Biopharmaceuticals has commenced dosing in its Phase 3 approval study PARA_OA_012 for osteoarthritis of the knee, with Bell Potter noting enrolment is underway in the US and Australia.

The trial will recruit 466 patients across up to 65 sites, with a futility analysis at 50% enrolment. This analysis checks whether it is realistically possible for the study to reach its primary endpoint if it continues as planned.

The broker highlights three differentiators versus peer failures: a conservative staged Phase 3 approach, saline as the control arm, and powering based on extensive prior data with a conservative effect size above approval thresholds.

These measures are expected to improve the chance of success.

Bell Potter makes no material forecast changes. The broker lowers its target to 65c from 73c following amendment to shares on issue following prospective new equity. A Buy (Speculative) rating is retained.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -10.90 cents.
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -11.20 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

PAR STOCK CHART

FNArena News on PAR

Latest Pharmaceuticals & Biotech/Lifesciences News

1
CSL: Buy Trigger Ahead

Apr 26 2022 - Technicals
2
Why CSL Fell Sharply Yesterday

Dec 17 2021 - Australia
3
Beating The Biotech Blues

Sep 14 2021 - International
4
Uncertainty Prevails For CSL

Aug 19 2021 - Australia
5
Flying High – Medicinal Marijuana In Australia

Jul 26 2021 - Australia
6
Wesfarmers On Drugs?

Jul 13 2021 - Australia
7
Is CSL’s Plasma Recovery Now Priced In?

Jun 23 2021 - Australia
8
CSL: Buy The Dip

Jun 22 2021 - Technicals
9
CSL To Retest Its High?

May 25 2021 - Technicals
10
Treasure Chest: CSL Plasma At Turning Point?

May 05 2021 - Treasure Chest